GSK surges 6.5% after $2.2 billion Zantac lawsuits settlement
Shares of GSK rose as much as 6.5% on Thursday after the British drugmaker agreed to pay up to $2.2 billion to settle ...
GSK shares jump on $2.2 billion Zantac settlement
GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits ...
Zantac’s Developer Settles Lawsuits Claiming Cancer Link
GSK, which developed and sold versions of the now-discontinued blockbuster heartburn drug, agreed to pay up to $2.2 billion.
Zantac maker GSK agrees to pay $2.3 bn in US settlements
British pharmaceutical company GSK said Wednesday it has agreed to pay $2.3 billion in the United States to put an end to ...
GSK to Pay Over $2 Billion in Bid to End Most U.S. Zantac Lawsuits
GSK agreed to pay more than $2 billion to settle almost all remaining liability cases in the U.S. over allegations its ...
GSK to settle 80,000 Zantac cases for up to $2.2 billion
The deal settles 80,000 US court cases related to allegations that Zantac was contaminated with a suspected carcinogen.
Business Times5d
GSK surges 6.5% after US$2.2 billion Zantac lawsuits settlement
SHARES of British drugmaker GSK rose as much as 6.5 per cent on Thursday (Oct 10), after it agreed to pay up to US$2.2 ...
Yahoo Finance5d
GSK shares jump on $2.2 billion Zantac settlement
Ranitidine, which was sold under the Zantac brand name, was pulled off the market in 2020 on concerns it could degrade into NDMA, a carcinogen, over time or when exposed to heat. The recall ...
London South East5d
GSK surges 6.5% after $2.2 bln Zantac lawsuits settlement
Top gainer on FTSE index, best one-day gain since Dec 2022 To record 1.8 billion pounds charge in Q3 results Oct 10 (Reuters) - Shares of GSK rose as much as 6.5% on Thursday after the British ...